ALC:NYSE
Alcon AG
$67.56
arrow_downward
-0.40%(-0.27) 1D
Oct 21, 10:11:00 AM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALC...
Open
$67.56
High
$68.09
Low
$67.20
Mkt. cap
27.74B
Avg. vol.
1.77M
Volume
164.06K
52-wk high
$87.64
52-wk low
$61.84
Beta
0.88
Shares outstanding
483.40M
No. of employees
25K
Open
$67.56
High
$68.09
Low
$67.20
Mkt. cap
27.74B
Avg. vol.
1.77M
Volume
164.06K
52-wk high
$87.64
52-wk low
$61.84
Beta
0.88
Shares outstanding
483.40M
No. of employees
25K
News stories
From web sources and news partners
Investing.com UK
·
17 hours ago
Alcon acquires Neurotech for $550m to expand retina portfolio By Investing.com
Yahoo Finance
·
17 hours ago
Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2
Stock Traders Daily
·
19 hours ago
Precision Trading with Alcon Inc. (ALC) Risk Zones
Profile
Alcon Inc. is a Swiss-American pharmaceutical and medical device company specializing in eye care products. Alcon is incorporated in the Canton of Fribourg, Switzerland, and its global headquarters are located in Geneva, but its main operational base is in Fort Worth, Texas, United States, where it employs about 4,500 people.
Alcon was a subsidiary of Novartis until April 2019, when it was spun out into a separate publicly traded company. Alcon itself has a number of subsidiaries, including Aerie Pharmaceuticals, focused on therapies for glaucoma and other diseases of the eye, and WaveLight, which develops and manufactures laser eye surgery technologies. Wikipedia
About Alcon AG
CEODavid J. Endicott
Employees25K
Founded1945
HeadquartersGeneva, Geneva, Switzerland
SectorMedical device
Websitealcon.com